What excites and concerns VillageMD’s CEO about the future of healthcare

The latest stories trending on MedCity News.

Editor's Pick

Top Story What Excites and Concerns VillageMD's CEO About the Future of Healthcare Tim Barry, CEO of VillageMD, is encouraged by the shift he's seeing to value-based care, but is worried that new technologies could create a fragmented system. He made these comments after the value-based company announced Thursday that it completed its $8.9 billion acquisition of Summit Health-City MD. Have You Submitted Your Application? INVEST 2023 Pitch Perfect Applications    There is no fee to apply. Only companies funded from 2018-2022 (no more than five years ago), and that have raised a seed funding round will be considered. Startups can apply to only one track. Startups must be registered for the conference in order to participate in the pitch contest. There are five tracks and each track will feature six finalists. Application Deadline: January 30, 2023. Applications will be reviewed by investment professionals and selections announced on Feb. 21, 2023.   Apply Now!

Featured News

Novellia founders seek to use digitomics, precision data to speed up drug development Healthcare startup Novellia's platform seeks to digitally bring in all chapters of a patient's health journey to allow clinicians and researchers to finally see the full story. Making Pharmacy Benefits Transparent and Returning Control to Patients and Employers Transcarent wants to transform the digital pharmacy benefit experience, enabling self-insured employers and their staff to make more informed choices. Can Data Solve Behavioral Health's Outcome Disparity Dilemma? Generally, behavioral health and substance use disorder are behind other specialties in collecting health equity data to lower outcome disparities. Data standardization, reporting requirements, and interoperability are critical to quickly addressing gaps. FDA Approval of Eisai Alzheimer's Drug Bears Imprint of Aduhelm Review Eisai Alzheimer's disease drug Leqembi is now approved for the treatment of patients with an early form of the memory-robbing disease. In granting the antibody accelerated approval, the FDA employed reasoning that was the also basis for the controversial speedy regulatory nod for Biogen's drug, Aduhelm. Zimmer Biomet Expands Sports Medicine Portfolio with $275M Acquisition Announcement Orthopedics giant Zimmer Biomet entered into a definitive agreement to acquire Embody, a company that makes collagen-based implants designed to heal soft tissue injuries. Zimmer Biomet pursued the deal to grow its sports medicine portfolio and gain entry into the high-growth rotator cuff augmentation submarket, an executive said.

Resources

MedCity News • 611 Broadway • New York, NY unsubscribe